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Detection of HER-2/neu, c-myc amplification and p53
inactivation by FISH in Egyptian patients with breast
cancer
Nachweis von HER-2/neu, c-myc-Amplifikation und p53-Inaktivierung
durch FISH bei ägyptischen Patienten mit Brustkrebs
Abstract
Breast cancer is a leading cause of cancer-related deaths in women
worldwide. The clinical course of this disease is highly variable and
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Hussein M. Khaled
3
ately predict prognosis, and indicate a suitable adjuvant therapy for
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2 eachpatient.AmplificationofthetwooncogenesHER-2/neuandc-myc
and inactivation of the tumor suppressor gene p53 are frequently en-
countered in breast carcinomas. The purpose of this study was to use
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p53 was significantly associated with increased patient’s age. The
sensitivityoftheinvestigatedmarkerssignificantlyincreasedwithlarger
tumor size. Concerning tumor grade, HER-2/neu and p53 showed a
significantincreaseinlow-gradetumorswhereasc-mycshowedahighly
significantincreaseinhigh-gradetumors.Withregardtodiseasestaging,
HER-2/neu and c-myc were the only markers that showed significant
increaseatlatestagesofdisease.p53andHER-2/neuweresignificantly
associated with positive lymph nodal status. A significant correlation
was obtained between the levels of the three biomarkers to each other.
Conclusively,thecombinationofHER-2/neu,c-mycandp53canstratify
patients into different risk groups.
Keywords:breastcancer,fluorescentinsituhybridization(FISH),genetic
alterations, HER-2/neu, p53, c-myc
Zusammenfassung
Brustkrebs ist weltweit die häufigste Ursache für krebsbedingte Todes-
fälle bei Frauen. Der klinische Verlauf bei dieser Erkrankung ist sehr
unterschiedlich, und Kliniker sind bemüht, prognostische Parameter
zu finden, die für jeden Patienten zuverlässig den Verlauf voraussagen
und eine geeignete adjuvante Therapie vorgeben können. Die Amplifi-
kation der zwei Onkogene HER-2/neu und c-myc und die Inaktivierung
des Tumorsuppressorgens p53 treten bei Brustkrebs häufig auf. Das
Ziel dieser Studie war es, mit dem Verfahren der Fluoreszenz-in-situ-
Hybridisierung(FISH)dieAmplifikationderbeidenOnkogeneHER-2/neu
und c-myc sowie die Inaktivierung des Tumorsuppressorgens p53 zu
messen und diese molekularbiologischen Marker mit den gebräuchli-
chen klinischen und pathologischen Angaben zu korrelieren.
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Research Article OPEN ACCESSDie Studie wurde an 34 Gewebeproben, die von 33 Frauen und einem
Mann mit Brustkrebs stammen, und 17 Proben, die von 16 Frauen und
einem Mann mit benignen Brustgewebeveränderungen gewonnen
wurden, durchgeführt. Die Ergebnisse zeigen, dass die Werte von HER-
2/neu, c-myc und p53 in der Krebsgruppe signifikant verändert waren
im Vergleich zu der Gruppe mit gutartigen Tumoren. Bei der Beziehung
der Gehalte der molekularen Marker zu den klinisch-pathologischen
Befunden waren die Befunde bei p53 signifikant mit dem Alter der Pa-
tientinkorreliert.DiediagnostischeSensitivitätderuntersuchtenMarker
war signifikant korreliert mit der Größe der Tumoren. Im Hinblick auf
dasTumorgradingzeigtenHER-2/neuundp53einesignifikanteZunah-
me bei low-grade-Tumoren, während c-myc eine signifikante Zunahme
bei high-grade-Tumoren aufwies. Bezüglich des Disease-Staging waren
HER-2/neuundc-mycdieeinzigenTumormarker,dieeinensignifikanten
Anstieg im letzten Stadium der Erkrankung aufwiesen. p53 und HER-
2/neu waren signifikant assoziiert mit positivem Lymphknotenstatus.
EinesignifikanteKorrelationbestandbeidenWertenderdreiBiomarker
untereinander.
Zusammenfassend kann die Bestimmung von HER-2/neu, c-myc und
p53indenGewebeprobendiePatienteninverschiedeneRisikogruppen
einteilen.
Schlüsselwörter:Brustkrebs,Fluoreszenz-in-situ-Hybridisierung(FISH),
genetische Veränderungen, HER-2/neu, p53, c-myc
Introduction
Breastcancerranksfirstamongcancersaffectingwoman
throughout the world and its marked impact is not re-
stricted to Western industrialized societies [49]. Latest
estimatessuggestthatmorethan1,050,000newbreast
cancer cases occur worldwide annually, with nearly
580,000casesindevelopedcountriesandtheremainder
in developing countries [17]. Breast cancer is the most
commonmalignancyamongEgyptianfemalesaccounting
about 37.6% of all malignancies in women [36]. Over the
threeyears2000–2002,1831breastcancercaseswere
registered; 1810 females and 21 males with an average
of 603 cases of female breast cancer per year.
The progression of malignant tumors is a consequence
of multiple alterations of the genome including either
activation of oncogenes such as HER-2/neu and c-myc
or inactivation of tumor suppressor genes such as p53
[54], [48], [8].
HER-2/neu oncogene is a member of the human epider-
mal growth receptor family [12]. The gene product is a
protein with extracellular and intracellular domain with
tyrosine kinase activity involved in signal transduction of
cell growth and development [23]. Amplification of the
HER-2/neureceptortyrosinekinasehasbeenimplicated
in the pathogenesis and aggressive behavior of approxi-
mately 25% of invasive human breast cancers. It has
beensuggestedthataberrantHER-2signalingcontributes
to tumor initiation and disease progression [52]. Deter-
mination of HER-2/neu in serum of patients with meta-
static breast cancer has proved clinical utility since it
correlateswithproteinexpressioninprimarytumors[53].
The c-myc oncogene has been shown to be amplified
and/or overexpressed in many types of cancer. The fre-
quencies of its amplification, mRNA and protein overex-
pression in breast cancer vary between 1%–94%,
22%–95%, and 50%–100%, respectively [26], [6]. c-myc
protein is a product of c-myc proto-oncogene and exerts
diverse effects on cell behavior. c-myc, being a transcrip-
tion factor, plays important role in cell growth and differ-
entiation and was found to be associated with a more
aggressive tumor and a poorer patient survival [33].
Thehumanp53geneencodesa53KDnuclearphospho-
proteinconsistingof393aminoacids[30].Wild-typep53
protein blocks the entry of cells into S phases whereby
allowing DNA repair to occur before replicating the gen-
ome. p53 can also induce apoptosis when DNA repair
fails [25]. However, not only mutant p53 cannot prevent
the propagation of genetically damaged cells but also
can inhibit apoptosis [27]. More recently, anti-p53 anti-
bodiesareofclinicalsignificanceasaserologicalmarker
in the diagnosis and monitoring of breast cancer [32].
To our knowledge, this is the first report to demonstrate
thegeneticalterationsinEgyptianbreastcancerpatients
using FISH technique.
In the current study, we assessed the genetic alterations
in HER-2/neu, c-myc and p53 genes using fluorescence
in situ hybridization (FISH) in Egyptian breast cancer pa-
tients and investigated the prognostic role of the three
markers and their relation to each other and to demon-
strate their relation to the classical clinicopathological
factors.
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Patients
Patientswithprimarybreastcancerhadeitheranexcision
biopsy with axillary evacuation or a modified radical
mastectomy in the surgical department at the National
Cancer Institute, Cairo University. No preoperative radi-
ation therapy or chemotherapy was administered to pa-
tients.
Thirty-fourconsecutivesampleswereobtainedduringthe
period from 1999–2001 from 33 females and 1 male
with breast carcinoma (27 with invasive duct carcinoma
and 7 with non-invasive duct carcinoma). The age of the
patientsrangedfrom23to75years.Seventeensamples
were obtained from 16 females and 1 male with benign
breast lesions to serve as a control group (12 with
fibroadenoma, 4 with fibrocyctic disease and 1 with
gynecomastia). The age of the patients ranged from
15–52years.Thehistologicgradesofthetumorfociwere
assessed using the modified Bloom-Richardson classifi-
cation [16]. Clinical staging was done according to TNM
classification [3]. Informed consent was obtained for all
cases.
Tissue samples were cut into pieces, one was formaline-
fixedandparaffin-embeddedforsubsequenthistopatho-
logical examination, and the second was shock-freezed
in liquid nitrogen and stored at –80°C for the analysis of
HER-2/neu, c-myc and p53.
Fluorescence in situ hybridization
analysis
Specimen preparation, hybridization, and microscopy
were performed as previously described [37], [38] with
the following modifications. Frozen-stored tissues were
slowly thawed in cold phosphate buffered saline (PBS)
at 4°C, light-touched on glass slides. Slides were incu-
bated in 75 mM KCl for 20 min at 37°C, fixed in freshly
prepared Carnoy’s solution (methanol : acetic acid, 3:1
v/v ) and air-dried.
The SpectrumOrange labeled HER-2/neu probe and the
SpectrumGreen chromosome 17 centromeric alpha-
satellite (chr.17cen.) probe were cohybridized on the tis-
sue specimen. For c-myc hybridization locus specific
identifier (LSI) c-myc (SpectrumOrange) and CEP8
(SpectrumGreen)probeandLSIp53probewereapplied.
FISH probes were obtained from Vysis, Inc, Downers
Grove, IL.
Thec-mycandHER-2genecopynumbersinapproximate-
ly 200 nuclei in the predominant tumor cell population
were estimated in relation with centromere CEP8 and
CEP17. Hybridization signals were enumerated by the
ratio of orange signals (for c-myc and HER-2) to green
signals (for CEP8 and CEP17) in morphologically intact
and nonoverlapping nuclei. At least a 3-fold increase of
the c-myc signals over CEP8 signals in the tumor cells
was considered the criterion for gene amplification. The
same criterion was applied to HER-2 amplification analy-
sis using LSI HER-2 probe together with CEP17 probe
[24], [9].
Statistical analysis
Cut-off values were determined using receiver operating
characteristic curve (ROC curve). The Mann-Whitney and
Wilcoxon tests, and univariate analysis were performed
using a chi-square test of association or Fisher’s exact
model to test the association of categorical variables,
whereast-testwasusedforcontinuousvariables.Pvalues
below 0.05 were considered as significant [2].
Results
Cut-off values for HER-2/neu and c-myc
The best cut-off values were estimated to maximize the
sum of sensitivityand specificity. Optimalcut-off valueof
1.2 for both HER-2/neuandc-myc areshown in Figure1.
Figure 1: ROC curve of both HER-2/neu and c-myc. The area
under the curve is 0.789 and 0.752 for HER-2/neu and c-myc,
respectively.
ExpressionofHER-2/neu,c-mycandp53
in benign and malignant groups
Genetic alteration in HER-2/neu, c-myc and p53 were
significantly higher in the malignant group when com-
pared to the benign one as show in Table 1. In the malig-
nantgroup,thelevels(mean,medianandpositivityrates)
for HER-2/neu are 2.8±0.17, 1.435 (0.9–4.2) and 85%
respectively, versus 1.25±0.11, 1.06 (0.86–2.5) and
29% in the benign group.
For c-myc, the levels (mean, median and positivity rates)
are1.89±0.13,1,825(0.95–3.53)and73%respectively
in the malignant group as compared to 1.2±0.08, 1.1
(0.87–2.02) and 35% respectively in the benign group.
0 (0–1) and 64% are the median and positivity rate, re-
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spectively for p53 in the malignant group in comparison
to 1 (0–1) and 17% in the benign group.
Relation between the investigated
molecular markers and
clinicopathological findings
The levels of the three investigated genes in relation to
theclinicopathologicalfactorswereshowninTable2and
Table 3. The results show positivity rate of HER-2/neu,
c-myc and p53 and their relation to clinicopathological
factors. At age <45, positivity rate of HER-2/neu, c-myc
andp53were12(75%),10(62.5%)and4(25%)respect-
ively, whereas at age >45 positivity rate of HER-2/neu c-
myc and p53 were 17 (94.44%), 15 (83.33%) and 18
(100%) respectively.
Inrelationtotumorsize,thepositivityrateofHER-2/neu,
c-myc and p53 were 7 (70%), 4 (40%) and 5 (50%) for
tumorsizelessthan3cmrespectively.Forthetumorsize
moreandequalto3cm,thepositivityrateofHER-2/neu,
c-myc and p53 were 22 (91.66%), 21 (87.5%) and 17
(70.83%) respectively. On the other hand the positivity
rate of HER-2/neu, c-myc and p53 were 25 (89.28%), 19
(67.85%) and 19 (67.85%) respectively in grade I & II
cases, whereas it was 4 (75%), 6 (100%) and 3 (50%)
respectivelyingradeIII.Concerningdiseasestaging,HER-
2/neu and c-myc were the only markers that showed
significant expression at late stages of disease (HER-
2/neu:2.86(1.27–4.2),2.63±0.23;c-myc:88.88%)than
inearlystages(HER-2/neu:1.35(1.22–3.24),1.69±0.2;
c-myc: 56.25%).
Regarding nodal status, p53 and HER-2/neu were
significantly expressed in patients with positive lymph
nodes (p53: 77.3%, HER-2/neu: 2.49±0.22) when com-
pared to those with negative lymph nodal status (p 53:
41.7%, HER-2/neu: 1.69±0.25).
Correlation tests
On relating the level of the three biomarkers to each
other, they exhibited a significant correlation with each
other(HER-2/neuandc-mycr=0.511,p=0.002;p53and
c-myc r=0.356, p=0.03; p53 and HER-2/neu r=0.432,
p=0.01) (Table 4) .
Positivity of the molecular markers in
benign and malignant groups
The number of cases that give positive results for the
three markers together (HER-2/neu, c-myc and p53)
constitute 46% and 12% in malignant and benign cases,
respectively. On the other hand, the percentage of nega-
tivity for the three markers is 3% and 52% in the malig-
nant and benign cases, respectively.
Discussion
Breastcancerisadiseasewithatremendousheterogen-
eityinitsclinicalbehavior.Itiswellknownthattheclinical
outcome of breast cancer patients depends on different
clinicopathologicalfactors,includingthemetastaticstatus
of the lymph nodes, tumor size, tumor grade, and histo-
pathological subtype, but there are other molecular
markersthatcanaidtheselectionofpatientsforadjuvant
therapies. These molecular markers split the apparently
uniform population into clear subpopulations so that the
therapies offered to patients may become a reflection of
theirindividualtherapeuticneeds,ratherthantheassump-
tion that all patients behave as the population median
[22].
In our study, we assessed the genetic alterations in HER-
2/neu,c-mycandp53genesthatarecommonlyreported
in human breast carcinomas. In the present study, the
genealterationswerestudiedusingFISHtechnique.FISH
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Table 3: The level of HER-2/neu, c-myc and their relation to clinicopathological factors
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technique is a useful method to evaluate metaphase
chromosomes or interphase nuclei to detect genetic ab-
errations in a variety of solid tumor. FISH analysis of in-
terphasenucleidetectsgeneticaberrationsthatarediffi-
cult to identify by conventional cytogenetic analysis [55],
[7].
Our results revealed that HER-2/neu was amplified in
85% of malignant breast tumors, but only in 29% of be-
nign tumors. Similar results were obtained by Grushko
et al. [21] and Park et al. [35]. In addition, to evaluate
the HER-2/neu status at the mRNA and DNA level of
breast carcinomas, Vanden Bempt et al. [51] studied 32
invasive duct carcinomas for the detection of HER-2/neu
mRNA levels by RT-PCR. Corresponding paraffin sections
wereexaminedbyFISH.Only28casesshowedincreased
levelsofHER-2/neumRNA.FISHanalysisshowedcorres-
ponding gene amplification in all 28 cases with 2 cases
showing peculiar amplification pattern. In almost all
cases, amplification of the HER-2/neu gene results in
protein overexpression and poor prognosis. Patients
whose tumors have HER-2/neu gene amplification have
a shorter disease-free survival time than patients whose
tumors exhibit a normal HER-2/neu gene copy number
[20].Inaddition,Yassinetal.[57]studiedtheexpression
of HER family in Egyptian breast cancer patients and re-
portedthatHER-2expressionwasencounteredin79.5%
byimmunohistochemistryversus81.6%byRT-PCR.Tubbs
et al. [50] using primary FISH testing in 742 consecutive
cases of breast cancer, reported 80% of the cases not
amplified for HER-2 (HER-2/CEP17=0.8–1.9), whereas
19% (142/742) of cases were HER-2 amplified (HER-
2/CEP17>or=2.0).
Asshowninourresults,HER-2/neupositivitysignificantly
associateswithtumorsizeandgrade.Similarresultswere
obtained by Almasri and Al Hamad [1] and Prati et al.
[42]. Regarding nodal metastasis, our results are in
agreement with other studies which reported that HER-
2/neu amplification has been strongly associated with
positivelymphnodes[44],[29].TheysuggestedthatHER-
2/neu oncogene may be a marker for aggressive clinical
behavior in breast cancer patients. In relation to stage,
HER-2/neu amplification was shown to be significantly
associated with late stages of the disease, confirming
previous reports [43], [47] that detected increased fre-
quency of HER-2/neu amplification, by FISH analysis, in
patients suffering from stages later than IIB based on
TNM staging system. HER-2/neu amplification detected
byFISHalsopredicteddisease-relateddeathindependent
of classical clinicopathological factors in breast cancer
patients who received adjuvant therapy [15].
Matrix metalloproteinases (MMPs), in particular the
gelatinases MMP2 and MMP9, are important mediators
of tumour invasion and metastasis. Decock et al. [14]
demonstratedthatpatientswithHER-2/neuoverexpress-
ingtumoursshowedanincreaseof27%inplasmaMMP2
activity,butnotinMMP9,comparedwithpatientswithout
overexpression, suggesting a role for HER-2/neu in the
signallingpathwaysofMMP2activationincarcinogenesis.
In our study, results showed that c-myc was amplified in
73% of malignant breast tumors, but only in 35% of be-
nignlesions.Similarly,Blancatoetal.[11]reportedahigh
proportion (70%) of breast carcinoma were amplified for
the c-myc gene. Also, Park et al. [35] found that 15.2%
of the breast cancer specimens were c-myc positive.
Blancatoetal.[11]reportedthatc-mycgeneamplification
using FISH was correlated with the percentage of tumor
cells which expressed high levels of its protein, as de-
tected by immunohistochemistry in invasive cells.
Results of the current study demonstrated a significant
relation between c-myc positivity and tumor size, grade
andstageofthedisease.Regardingtumorsize,Aulmann
et al. [5] examined c-myc oncogene amplification using
FISHinaseriesof96pureductalcarcinomainsitu(DCIS)
and observed that c-myc oncogene amplification was
significantly associated with larger tumor size. They con-
cluded that c-myc oncogene appears to be involved in
thedevelopmentofamoreaggressivephenotypeofDCIS.
Shanmugham et al. [46] reported that c-myc expression,
assessed by immunohistochemical staining, showed a
positive association with increasing grade. With regard
to disease staging, Yang et al. [56] and Aulmann et al.
[4] showed a significant association between c-myc ex-
pression and amplification, respectively, and advanced
clinical stage of the disease. They implicated the role of
c-myc in tumor development and consequently disease
progression.
Resultsofthepresentstudyrevealedthatp53mutations,
assessed by FISH, were detected in 64% of malignant
cases but only in 17% of benign tumors. This finding is
in agreement with the study of Lukas et al. [28], which
investigated p53 mutation in breast carcinoma in situ
(CIS) using immunohistochemical method. They have
shown that p53 protein overexpression was identified in
22% of pure intraductal breast carcinomas and in 35%
of breast CIS with invasive disease. Recently, Peng et al.
[39]reportedanincreaseinthelevelofp53geneexpres-
sion in breast cancer using molecular beacon imaging
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detected in benign breast tumors. This is consistent with
the study of Rohan et al. [45] who demonstrated that
accumulationofp53proteininbenigndiseasewasasso-
ciated with an increased risk of progression to breast
cancer.
As shown in our results, p53 positivity is significantly as-
sociated with age of the patient, size and histological
grade of the tumor and positivity of lymph nodes.
Pietiläinenetal.[40]analyzedfemalebreastcarcinomas
immunohistochemically for p53 expression. They found
that high fraction of p53-positive nuclei was significantly
related to patient age under 70 years. Moreover, Gion et
al.[18]reportedthatyoungeragewasrelatedtolowp53
values in breast cancer patients. Regarding tumor size,
Overgaard et al. [34] demonstrated that TP 53 gene
mutations were significantly more frequent in tumors of
large size. In addition, Montero et al. [31] found a signifi-
cantrelationbetweenp53positivityandtumorsize.With
regard to the histological grade, our results showed that
p53mutationwassignificantlyassociatedwithlowhisto-
logical grade, a finding that is contradictory to that of
Bertheau et al. [10] and Goel et al. [19]. They reported
that p53 positivity is significantly associated with high
histological grade. This controversy could be referred to
the small number of grade III tumors included in our
study.Regardinglymphnodestatus,PratapandShousha
[41] demonstrated that p53 positivity was significantly
related to the presence of extensive axillary lymph node
metastasis, a finding that is in harmony with our results.
In addition, Cianga et al. [13] reported that 77.2% of the
primary breast carcinomas and 75% of the lymph nodes
metastases are positive for von Willebrand factor, a
marker of the endothelial cells, and this positivity is
significantly correlated with the expression of p53, sup-
porting the idea that angiogenesis is a marker for tumor
aggressivenessandp53couldbeinvolvedinthisprocess.
In conclusion, future studies must be completed that in-
cludelargerdatabasesofpatients,whichintegrateclinic-
al, pathologic, and molecular oncogene parameters. The
merging of these data may provide the clinician with an
enhancement of prognostic information that accurately
predicts the aggressive phenotype for breast cancer.
Thereafter, decisions regarding the necessity to adminis-
ter and delete adjuvant therapies will gain scientific
credibility.
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